Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Agilent Expands Cell Analysis R&D Capabilities in Ireland

Agilent Technologies Inc.
Posted on: 16 Nov 18

Agilent Technologies Inc. (NYSE: A) today announced the opening of a new, purpose-built extension to its Little Island, Cork facility in Ireland. The campus will focus on developing advanced technologies for the analysis of live-cells in real-time.

The expanded state-of-the-art facility incorporates recently acquired Luxcel Biosciences, adding real-time, fluorescence plate reader-based in vitro cell assay kits to Agilent’s cell analysis portfolio. The complex will house two new laboratories, one dedicated to cell analysis technologies, and the other to develop biosensors and related bio assay solutions.

Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in the development of specialized instruments and live-cell, kinetic assays. The addition of Luxcel expands Agilent's cell analysis portfolio and brings new capabilities through technology and research which will drive advancements in this fast-evolving field for Agilent globally.

“Technological progression allowing researchers to examine cell health and function kinetically, and in real-time, are driving global demand for complete cell analysis solutions,” said Todd Christian, general manager, Agilent Cell Analysis Division. “The Luxcel acquisition and Agilent Ireland expansion underscore Agilent’s continued commitment to the growing cell analysis market.”

“We’re excited that Agilent has invested in Ireland,” said Martin Shanahan, chief executive officer, IDA Ireland. “Luxcel has partnerships and active research programs in Ireland, and with major EU and UK research institutions. This expansion will not only provide the most up-to-date and advanced solutions for Agilent’s customers but will have a significant positive impact within the Irish and European innovation ecosystem.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181116005009/en/

Business Wire
www.businesswire.com

Last updated on: 16/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.